Proven Intelligence for UK and EU Regulatory Submissions.

A successful Scientific Advice meeting with the UK’s MHRA is built upon a cohesive narrative that directly translates preclinical findings into a defensible clinical strategy. This involves prospectively designing IND-enabling toxicology studies to answer questions about dose selection, safety margins, and the biological plausibility of the therapeutic approach. The objective is to present a data-driven rationale that minimizes clinical risk and aligns with MHRA expectations for Advanced Therapy Medicinal Products (ATMPs).

Frequently Asked Questions

Q: What is the primary objective when presenting preclinical data during an MHRA Scientific Advice meeting for an ATMP?

The primary objective is to demonstrate a clear and logical link between the nonclinical data and the proposed clinical trial design. This includes justifying the first-in-human (FIH) starting dose based on efficacy and toxicology data from relevant animal models, defining the safety margins, and providing a data-supported rationale for the patient population and monitoring plan.

Q: How does Franklin Biolabs ensure our preclinical data package is suitable for an Investigational Medicinal Product Dossier (IMPD) submission in the UK?

We design and execute studies under GxP conditions with the IMPD structure in mind from the outset. Our study directors develop a phase-appropriate strategy that aligns with both MHRA guidelines and broader ICH standards, ensuring the data on manufacturing, toxicology, and pharmacology is presented in a format that facilitates efficient regulatory review for UK and EU submissions.

Q: For a novel AAV vector, what specific preclinical data does the MHRA focus on?

The MHRA places significant emphasis on the rationale for vector design, including capsid and promoter selection. Key data points include in vivo proof-of-concept showing target engagement, dose-response studies to identify a minimally effective dose, and comprehensive toxicology and biodistribution studies, particularly assessing non-target tissue biodistribution and the potential for immunogenicity.

Building a Defensible Regulatory Narrative

Engaging with the MHRA is a pivotal step in the clinical translation of next-generation therapies. The agency’s Scientific Advice provides an opportunity to de-risk the clinical development plan, but its value is contingent on the quality of the preclinical data package and the clarity of the narrative it supports. A simple transfer of raw data is insufficient. The data must be curated to build a logical argument for the safety and potential efficacy of the proposed therapeutic.

This process begins with study designs that anticipate key regulatory questions. A standard, template-driven approach to preclinical testing does not exist for these complex modalities. Instead, a tailored strategy is required, focusing on the specific biology of the asset and the intended clinical indication.

Justifying Dose Selection with Efficacy Data

A core component of the MHRA submission is the justification for the proposed clinical starting dose. This requires robust preclinical data demonstrating a clear dose-response relationship and establishing a minimally effective dose (MED) in a relevant biological system. For instance, preclinical programs for AAV-based therapies have successfully used animal models to define the MED needed to achieve a therapeutic effect, while simultaneously establishing a safety window at higher dose levels (PMID: 34652966).

This data is foundational to the clinical plan. It allows for a data-driven starting dose selection that balances the potential for efficacy against safety considerations. Further evidence demonstrating sustained functional correction of disease biomarkers in preclinical models provides direct support for the therapeutic hypothesis and the durability of the effect, a key point of interest for regulators (PMID: 22133298).

Integrated Safety and Biodistribution Analysis

The safety profile presented to the MHRA must be comprehensive. This extends beyond standard toxicology endpoints to include a detailed assessment of vector biodistribution and potential immunogenicity. Our work within our >100,000 sq ft preclinical facility focuses on generating this data under GxP conditions.

A deep understanding of non-target tissue biodistribution is necessary to predict and monitor for potential off-target effects in the clinic. This integrated approach to safety and pharmacology has been central to the track record of our core scientific team, which has maintained a 100% successful IND submission rate since 2019. While Franklin Biolabs formally launched in 2024, this history of success reflects the deep experience of our principal scientists in navigating complex regulatory expectations for next-generation therapies, including our work supporting the Moderna collaboration. This expertise is applied to programs targeting UK and EU submissions, ensuring alignment with international standards.

Our approach is designed to deliver a complete data package that supports an accelerated path to the clinic, consistent with our 18-24 month candidate-to-IND timeline. For a deeper look at our capabilities, explore our core Preclinical and Translational Services.

---

---